Full text is available at the source.
Starting Higher Doses of Tirzepatide Soon After Switching from Semaglutide in Type 2 Diabetes
Updated
Abstract
The 10 mg dose of tirzepatide resulted in a significant reduction in glycated hemoglobin (HbA1c) by 0.7% after switching from semaglutide.
- Fifteen patients with type 2 diabetes switched from 1.0 mg of semaglutide to tirzepatide due to inadequate weight loss.
- All patients began tirzepatide treatment at a dose of 2.5 mg, which was adjusted to either 7.5 mg or 10 mg.
- The group receiving 10 mg of tirzepatide showed a significant improvement in glycemic control compared to baseline.
- The same group exhibited a non-significant trend toward weight loss, averaging -6.6 kg.
- No significant changes in HbA1c or body weight were observed in the 7.5 mg group.
- No statistically significant differences were found between the two dosage groups.
Simplified